The estimated pulmonary artery pressure can be elevated in Behçet’s syndrome  by Seyahi, Emire et al.
Respiratory Medicine (2011) 105, 1739e1747ava i lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / rmedThe estimated pulmonary artery pressure can be
elevated in Behc¸et’s syndromeEmire Seyahi a,*, Murat Baskurt b, Melike Melikoglu a, Canan Akman c,
Deniz Cebi Olgun c, Eda Simsek d, Vedat Hamuryudan a, Serdar Kucukoglu b,
Hasan Yazici aaDivision of Rheumatology, Department of Medicine, Cerrahpas‚a Medical Faculty, University of Istanbul, Istanbul, Turkey
bDepartment of Cardiology, Institute of Cardiology, University of Istanbul, Istanbul, Turkey
cDepartment of Radiology, Cerrahpas‚a Medical Faculty, University of Istanbul, Istanbul, Turkey
dDepartment of Medicine, Cerrahpas‚a Medical Faculty, University of Istanbul, Istanbul, Turkey
Received 30 January 2011; accepted 27 July 2011
Available online 8 September 2011KEYWORDS
Behc¸et’s syndrome;
Systemic sclerosis;
Pulmonary artery
involvement;
Estimated pulmonary
artery pressure;
Echocardiography;
Dyspnea* Corresponding author. Halaskargaz
5890808.
E-mail address: eseyahi@yahoo.co
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2011.07.022Summary
Objectives: To determine the frequency of elevated systolic pulmonary artery pressure (sPAP)
estimated by echocardiography in Behc¸et’s syndrome (BS) patients with pulmonary artery
involvement (PAI), in healthy controls and in diseased controls with systemic sclerosis (SSc),
as well as in BS patients without PAI.
Methods: We studied 3 groups of patients with BS (patients with PAI: n Z 30, with vascular
disease but without PAI: n Z 26 and without vascular disease: n Z 21), patients with SSc
(n Z 23) and healthy controls (n Z 22). Systolic pulmonary artery pressure (sPAP) was esti-
mated by echocardiography. The upper limit for a normal sPAP was arbitrarily set at 35 mmHg.
We also evaluated cardiac function by echocardiography. Pulmonary function tests, a six-
minute walking test (six-MWT) and several serum biomarkers were also studied.
Results: The frequency of patients with an elevated sPAP was significantly higher only among
BS patients with PAI (17%) and among patients with SSc (26%). In addition, DLCO was decreased
and pro-BNP levels were increased in BS patients with PAI, which are similar to the results in
patients with SSc. Furthermore, BS patients with PAI also had mild RV diastolic dysfunction.
Conclusions: When BS involves the pulmonary arteries, it can cause mild elevations in the esti-
mated sPAP, decrease in DLCO, mild cardiac dysfunction and increase in pro-BNP levels. These
findings suggest that BS can also affect the small/micro vessels of the heart and the lungs in
addition to the well-recognized large vessel disease.
ª 2011 Elsevier Ltd. All rights reserved.i Cad. No: 209-211, Huzur ap. D: 2, Sisli, Istanbul 34360, Turkey. Tel.: þ90 533 8184234; fax: þ90 212
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1740 E. Seyahi et al.Behc¸et’s syndrome (BS)may involve pulmonary arteries in the
form of aneurysms (PAA), thrombosis (PAT) or occlusions.1e5 obstructive pulmonary disease, chronic hematologicalPulmonary artery involvement (PAI) is observed with
a frequencyof 1e2% inBSpatients fromendemicareas.1,2 PAA
in BS patients is associated with a high mortality rate usually
due tomassive hemoptysis that is caused by the rupture of an
aneurysm into a bronchus.1e5 PAT in BS differs from classic
pulmonary thromboembolic disease because the arterial
occlusion primarily results from an in situ thrombosis that
complicates anunderlying vasculitis.3e8 Pulmonary arteritis is
the primary underlying pathology based on post-mortem
examinations,3 but pulmonary arteritis is rare in garden
variety pulmonary thromboembolisms.9 Despite the high
prevalence of lower extremity deep venous thrombosis (DVT)
in BS patients, pulmonary embolism is rare.1e8,10 In a radio-
logical surveyof 41patientswithPAI,wenotedpreviously that
a portion of these patients had an increased systolic pulmo-
nary artery pressure (sPAP) estimated by echocardiography.11
Furthermore, the mean sPAP was significantly higher in
patients who had died due to PAI compared to patients who
had survived.11 Similarly, there have been sporadic reports
about pulmonary artery hypertension (PAH) developing in BS
patients with PAA.3,12,13
These preliminary observations led us to investigate esti-
mated sPAP levels and potentially associated clinical and
laboratory abnormalities inBSpatients and in suitable healthy
and diseased controls in a formal study. We used echocardi-
ography, a non-invasive method, to estimate sPAP because
the gold standard, right heart catheterization, unfortunately
carries the unusual risk of causing aneurysms or occlusions at
the vascular puncture sites in BS patients.14e16
Methods
We studied consecutive outpatients with BS and SSc who
were seen at the Division of Rheumatology of the Cerrah-
pasa Hospital at the University of Istanbul between April
2008 and June 2009. Patients with BS and SSc participated
in the study if they fulfilled the ISG and ACR criteria for
either disease, respectively.17,18
The following three subsets of patients with BS were
studied.
a. Patients with PAI were defined as BS patients who had
been diagnosed with PAA or PAT based on computerized
tomography (CT) scans. They may or may not have had
extra-thoracic vascular disease.
b. Patients with vascular disease without PAI were defined
as BS patients with no PAI but with additional extra-
thoracic vascular disease. The absence of PAI was
confirmed with a thorax CT scan.
c. Patients with no vascular disease were defined as BS
patients with no prior history of vascular disease.
Eligible patients were screened with a lower extremity
Doppler ultrasonography (USG) and a thorax CT.
Apparently healthy members of the hospital staff who
volunteered to participate in the study were included as
healthy controls.
Patients and controls were excluded if they had previous
diagnoses of heart disease (congenital, valvular, ischemicor congestive), portal hypertension, sarcoidosis, chronic
problems or any cardiopulmonary condition other than the
vascular conditions related to BS or SSc.
Study design
Information on clinical characteristics, disease duration
and current medications were obtained from medical
records. Study subjects were prospectively asked to
complete a standard questionnaire that assessed pulmo-
nary symptoms, such as fatigue, cough, exercise-induced or
resting shortness of breath, chest pain and hemoptysis, and
included questions on smoking history and previous diag-
noses of diabetes mellitus or hypertension. Venous Doppler
USG of lower extremities was obtained for all BS patients.
Thorax CT scans were performed in all BS and SSc patients.
Moreover, ECG recordings, echocardiography, six-minute
walking test (six-MWT), pulmonary function tests (FVC,
FEV1, TLC, DLCO) and serum biomarkers, including
endothelin-1 (ET-1), pro-brain natriuretic peptide (pro-
BNP) and vascular endothelial growth factor (VEGF), were
obtained for all study participants. In each patient, all
studies were completed in less than a month.
The study protocol was approved by the ethics
committee of the Cerrahpasa Medical Faculty, and written
informed consent was obtained from all study participants.
Echocardiography
Echocardiographic measurements were performed by
a cardiologist (MB) who was blinded to the clinical diag-
noses. Complete 2-D, M-Mode and Doppler echocardio-
graphic imaging were performed using an Acuson Sequoia
C256 and a 3.2 MHz transducer (Siemens Medical Solutions,
Mountain View, CA, USA).
LV diameters, fractional shortening, septal end-diastolic
thickness, posterior wall end-diastolic thickness, LV ejection
fraction (EF), end-diastolic RV diameter, thickness of the RV
free wall, RV outflow tract diameter, end-diastolic and
systolic RV areas and left and right atrial size/area at end-
systole were determined from M-mode tracings and 2-D
views according to established standards.19 Early diastolic
(tricuspid E) and late diastolic (tricuspid A) velocities of
tricuspid inflow were also calculated. RV EF was estimated
by the following calculation: (RV end-diastolic volume-RV
end-systolic volume)/RV end-diastolic volume  100.20
Tracings of the RV endocardium volumes at end-systole
and end-diastole were calculated by visually assessing the
largest and smallest RV chamber size. Tricuspid annular
plane systolic excursion (TAPSE) and pulsed Doppler tissue
imaging (DTI) were performed as described previously.21,22 A
myocardial systolic wave (systolic velocity) and two diastolic
waves, the early diastolic (Em) and late diastolic atrial
contraction (Am), were recorded. Isovolumic contraction
times (IVCTs), isovolumic relaxation times (IVRTs) and
ejection times (ETs) were also obtained from DTI, and the
myocardial performance index (Tei index) was calculated as
follows: (IVCT þ IVRT)/ET.22,23 The peak estimated sPAP was
calculated as described previously.24,25 sPAP was calculated
by the addition of an estimation of right atrial pressure
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gradient (PG). PG was calculated by the application of the
modified Bernoulli equation, DP Z 4V2, where DP is the PG
and V is the maximal velocity of the tricuspid regurgitation
jet. sPAP was considered normal when the tricuspid regur-
gitation could not be evaluated, assuming that there was no
right ventricle outflow tract obstruction. An estimated
sPAP  35 mmHg was used as a cut-off value to define
patients with elevated levels. Intra-observer variability in
the estimation of sPAP was assessed by the repeated eval-
uation of 23 randomly selected participants after 1e2
months. Intra-observer agreement was acceptable (k Z 0.8
at a cut-off  30 mmHg; k Z 0.6 at a cut-off  35 mmHg).
Statistical analyses
Continuous variables with a more or less normal distribution
are expressed as means  SDs, and other variables are
expressed as medians and interquartile ranges [IQRs].
Categorical variables were compared using the chi-square
test or Fisher’s exact tests where appropriate. Comparisons
of continuous variables were performed using Student’s t-
tests and one-way ANOVA followed by a post hoc Tukey’s
HSD test. Continuous variables with non-normal distribu-
tions were compared using the ManneWhitney U and
Kruskal Wallis tests with Bonferroni corrections. All statis-
tical analyses were performed using SPSS software (version
13.0 for Windows; SPSS, Chicago, IL).
Results
The demographic and clinical characteristics of BS patients
and controls are shown in Table 1. Age and gender ratios
were similar between the BS subgroups and the healthy
controls. Patients with SSc were more likely to be female
and older. Patients with SSc and BS patients with vascular
disease without PAI had longer disease duration. Interest-
ingly, a smoking history was positive in about half of the BS
patients both with and without vascular disease but was
significantly lower among BS patients with PAI.
Disease characteristics of the BS groups and SSc
patients (Table 1)
Patients with PAI (n Z 30; 27 M/3F)
The median disease duration for BS patients was 8 years
[IQR: 6e11], and the median disease duration for patients
with PAI was 4 years [IQR: 2e9]. PAI was newly diagnosed
(within 3 months) in only 3 patients. In the remaining
patients, the duration of PAI was longer than 1 year. The CT
scans that were taken at the time of diagnosis showed PAA
as the main lesion in 26 patients (87%) and pulmonary
thrombosis in the remaining 4 patients (13%). Based on
thorax CTs that were taken at the time of the study, active
disease, as evidenced by PAA (n Z 4) or PAT (n Z 1), was
present in only 5 patients (17%). In the remaining 25
patients (83%), PAA had disappeared, and the disease was
considered to be in remission. There were residual imaging
findings, such as stenosis or occlusion, in 16/25 patients
(64%). Pulmonary vessels appeared normal in the remaining
9 patients.In addition to pulmonary artery disease, this group of
patients (nZ 30) also had extra-thoracic vascular diseases,
such as lower extremity DVT (63%) and inferior (7%) and
superior (7%) vena caval thromboses (Table 1).
Patients with vascular disease without PAI (nZ 26; 23M/
3F)
The median disease duration for BS patients was 12 years
[IQR: 8e17], and the median duration of vascular involve-
ment was 7 years [IQR: 3e10]. As shown in Table 1, these
patients had extensive vascular involvement, such as lower
extremity DVT (88%), vena cava inferior (50%) and superior
thromboses (27%) and peripheral arterial disease (15%).
Patients with no vascular disease (n Z 21; 19M/2F)
The median disease duration of BS was 10 years [IQR:
5e12]. Three patients had mild eye disease.
Patients with SSc (n Z 23; 2M/21F)
We studied 23 (2 M/21 F) patients with SSc who were seen
consecutively in the rheumatology outpatient clinic. Six
(26%) had diffuse SSc, and the remaining 17 (74%) had limited
SSc. Eighteen (78%) had interstitial lung disease (ILD).
Current drugs (Table 1)
BS patients with vascular disease with or without PAI used
primarily azathioprine and corticosteroids, and less
frequently cyclophosphamide or interferon. However, BS
patients with no vascular disease primarily used colchicine
and azathioprine. Patients with SSc primarily used corti-
costeroids and methotrexate. All SSc patients used nifedi-
pine, and about ¼ were additionally treated with aspirin.
Estimated sPAP measurements (Table 2)
Six (26%) patients with SSc, 5 (17%) BS patients with PAI and
2 (8%) BS patients with vascular disease without PAI had
sPAP values  35 mmHg. None of the BS patients without
vascular disease or healthy controls had sPAP values 
35 mmHg (P Z 0.014) as shown in Table 2. When patients
with SSc were excluded, BS patients with PAI were more
likely to have a sPAP value  35 mmHg, but this was only
observed compared to healthy controls (P Z 0.058).
Pulmonary symptoms (Table 3)
Exercise-induced dyspnea was present in about half of the
BS patients with vascular disease with or without PAI and in
patients with SSc. Except for 3 patients (1 M/2 F), all
patients with SSc described dyspnea on exertion that was,
class II according to NYHA classification.25 Two patients
with SSc had class III dyspnea, and 1 patient had class IV
dyspnea. Cough and hemoptysis were significantly more
common in only among BS patients with PAI.
Pulmonary function studies (Table 3)
FVC, FEV1 and TLC were significantly low in patients with
SSc. DLCO was significantly reduced in patients with SSc and
in BS patients with PAI.
Table 1 Demographic and clinical characteristics and medications of study participants.
Patients with Behc¸et’s syndrome Patients with
SSc (n Z 23)
Healthy
controls
(n Z 22)
P
Pulmonary artery
involvement (PAI)
(n Z 30)
Vascular
disease
(without PAI)
(n Z 26)
Without
vascular
disease
(n Z 21)
Male/Female 27/3 23/3 19/2 2/21 20/2 <0.001a,b,c,d
Mean age, years 34  8 38  8 35  6 48  10 36  7 <0.001a,b,c,d
Disease duration, years 9  6 13  7 10  5 13  9 e 0.033
Hypertension, n (%) 1 (3) 5 (19) 1 (5) 1 (4) 1 (5) 0.144
Diabetes mellitus, n (%) 0 2 (8) 0 2 (9) 0 0.185
Smoking, n (%) 7 (23) 12 (46) 10 (48) 2 (9) 14 (64) 0.001b,c,d,f
Lower extremity DVT, n (%) 19 (63) 23 (88) e e e 0.016
VCI thrombosis, n (%) 7 (23) 13 (50) e e e 0.038
VCS thrombosis, n (%) 2 (7) 7 (27) e e e 0.156
Other arterial disease, n (%) 2 (7) 4 (15) e e e 0.293
Current drugs, n (%)
Azathioprine 19 (63) 16 (62) 5 (24) 2 (9) e <0.001a,b,e
Corticosteroids 11 (37) 9 (35) 1 (5) 15 (65) e 0.001a,b,c,e,g
Cyclophosphamide 4 (13) 2 (8) 0 2 (9) e 0.232
Interferon 0 3 (12) 0 0 e e
Methotrexate 0 0 0 8 (35) e e
Colchicine 0 1 (4) 10 (48) 0 e e
Calcium channel blockers 0 0 0 23 (100) e e
ACE inhibitors 1 (3) 1 (4) 0 2 (9) e 0.526
Diuretics 1 (3) 1 (4) 0 0 e 0.654
Anti-aggregant 1 (3) 6 (23) 0 6 (26) e 0.018a,c,e,g
Anti-coagulant 0 0 0 2 (9) e 0.544
PAI: pulmonary artery involvement, DVT: deep vein thrombosis, VCI: vena cava inferior thrombosis, VCS: vena cava superior thrombosis.
a SSc vs. PAI.
b SSc vs. vascular disease without PAI.
c SSc vs. without vascular disease.
d SSc vs. healthy controls.
e Vascular disease without PAI vs. without vascular disease.
f PAI vs. healthy controls.
g PAI vs. vascular disease without PAI.
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The six-MWT distance was significantly diminished in
patients with SSc and in BS patients with vascular disease
without PAI.Table 2 Systolic pulmonary artery pressure estimates (sPAP) in
Patients with Behc¸et’s syndrome
Pulmonary artery
involvement (PAI)
(n Z 30)
Vascular
disease
(without PAI)
(n Z 26)
W
va
di
(n
Patients with sPAP
level of 35
mmHg, n (%)
5 (17) 2 (8) 0
Values (35 mmHg) 35, 35, 39, 40, 45 35, 35 e
a PAI vs. without vascular disease.
b PAI vs. healthy controls.
c SSc vs. without vascular disease.
d SSc vs. healthy controls.Serum biomarkers (Table 3)
The frequency of patients with detectable ET-1 levels was
significantly high only among the patients with SSc. Simi-
larly, serum levels of pro-BNP were highest in patients withthe study groups.
Patients with
SSc (n Z 23)
Healthy
controls
(n Z 22)
P
ithout
scular
sease
Z 21)
6 (26) 0 0.014a,b,c,d
35, 35, 40, 40, 55, 60 e e
Table 3 Pulmonary symptoms, respiratory functions, six-MWT and serum biomarkers in study participants.
Patients with Behc¸et’s syndrome Patients with
SSc (n Z 23)
Healthy
controls
(n Z 22)
P
Pulmonary artery
involvement (PAI)
(n Z 30)
Vascular
disease
(without PAI)
(n Z 26)
Without vascular
disease (n Z 21)
Pulmonary symptoms, n (%)
Exercise-induced dyspnea 16 (53) 11 (42) 1 (5) 13 (57) 0 <0.001a,b,c,d,e,f
Fatigue 8 (27) 6 (23) 5 (24) 9 (39) 1 (5) 0.093
Coughing 13 (43) 3 (12) 0 2 (9) 0 <0.001a,b,g,h
Chest pain 5 (17) 1 (4) 0 0 2 (9) 0.071
Hemoptysis 9 (30) 0 0 0 0 e
Respiratory functions, %
FVC 99  13 97  17 99  15 81  17 101  15 <0.001e,f,g,i
FEV1 93  13 94  19 101  20 77  15 98  14 <0.001e,f,g,i
TLC 95  9 97  5 98  13 72  18 94  15 <0.001e,f,g,i
DLCO 72  15 93  4 93  16 57  27 93  17 <0.001e,f,b,i
Six-MWT, m 489  79 448  107 508  88 391  96 544  71 <0.001e,c,g,f
Biomarker levels
ET-1, detectable
levels, n (%)
2 (7) 4 (15) 1 (5) 1 (4) 7 (32) 0.030g,e,f
Pro-BNP (fmol/mL) 680  383 565  172 570  192 831  311 457  112 <0.001b,e,f,i
VEGF (pg/mL) 548  327 601  791 390  225 521  309 494  320 0.626
PAI: pulmonary artery involvement, DVT: deep vein thrombosis, VCI: vena cava inferior thrombosis, VCS: vena cava superior thrombosis,
FVC: forced vital capacity, FEV1: forced expiratory volume in the first second, TLC: total lung capacity, DLCO: diffusing capacity of
carbon monoxide, Six-MWT: six-minute walking test, ET-1: Endothelin-1, Pro-BNP: pro-brain natriuretic peptide, VEGF: vascular
endothelial growth factor.
a PAI vs. without vascular disease.
b PAI vs. healthy controls.
c Vascular disease without PAI vs. healthy controls.
d Vascular disease without PAI vs. without vascular disease.
e SSc vs. without vascular disease.
f SSc vs. healthy controls.
g PAI vs. SSc.
h PAI vs. vascular disease without PAI.
i SSc vs. vascular disease without PAI.
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had significantly higher pro-BNP levels; however, this result
was only true when compared to the healthy controls. VEGF
levels were similar among the study groups.
ECG (Table 4)
ECG abnormalities were significantly more common in the
SSc patients (39%) compared to the other groups. However,
a considerable portion of BS patients with PAI (23%) also had
ECG abnormalities. The heart rate was similar between the
study groups.
Systolic and diastolic functions of the left and right
ventricles (Table 5)
BS patients with vascular disease with and without PAI had
significantly lower LV end-systolic dimension and LV frac-
tional shortening. Patients with PAI had significantly lower
LV EF, but this result was true only when compared to the
healthy controls. The RVOT systolic amplitude was signifi-
cantly higher in BS patients with vascular disease with and
without PAI. Similarly, a trend toward a higher RV diastolicsurface was observed in BS patients with vascular disease
with and without PAI.
Variables associated with an elevated estimated sPAP
(Table 6)
No study variable, including the echocardiographic param-
eters, differed significantly between patients with and
without an elevated sPAP among the BS patients with PAI.
sPAP levels were also similar between patients with and
without active PAI. However, a trend toward an increased
prevalence of ECG abnormality was observed in BS patients
with PAI with elevated sPAP levels (P Z 0.068).
Discussion
In this study, we observed that BS patients with PAI had
mildly elevated estimated sPAP levels. Additionally, they
had lower DLCO and higher pro-BNP levels compared to
healthy controls. However, no study variable was particu-
larly different between patients with and without elevated
sPAP. Whether the modest estimated sPAP elevations in BS
patients that we observed are clinically important requires
Table 4 ECG abnormalities in study participants.
Patients with Behc¸et’s syndrome Patients with
SSc (n Z 23)
Healthy
controls
(n Z 22)
P
Pulmonary artery
involvement
(PAI) (n Z 30)
Vascular
disease
(without PAI)
(n Z 26)
Without
vascular
disease
(n Z 21)
Patient with ECG abnormality, n (%)
Atrial premature contraction 0 0 0 1 (4) 1 (5) 0.487
Ventricular premature
contraction
0 1 (4) 0 3 (13) 0 0.043
Conduction disturbance
(RBBB)
2 (7) 0 0 1 (4) 1 (5) 0.589
Left ventricular hypertrophy 1 (3) 0 0 1 (4) 0 0.590
Right ventricular
hypertrophy
1 (3) 0 0 0 0 0.548
Right axis deviation 1 (3) 0 0 1 (4) 0 0.590
Left axis deviation 0 1 (4) 1 (5) 3 (13) 0 0.119
T wave change 2 (7) 0 0 0 0 0.187
Any abnormality 7 (23) 2 (8) 1 (5) 9 (39) 2 (9) 0.006a,b,c
Heart rate/min 85  16 86  20 77  16 82  13 77  18 0.232
a SSc vs. BS patients with vascular disease without PAI.
b SSc vs. BS patients without vascular disease.
c SSc vs. Healthy controls.
Table 5 Echocardiography parameters in study participants.
Patients with Behc¸et’s syndrome Patients with
SSc (n Z 23)
Healthy
controls
(n Z 22)
P
PAI
(n Z 30)
Vascular
disease
(without PAI)
(n Z 26)
Without
vascular
disease (n Z 21)
LV end-diast. d., mm 47.9  3.8 48.6  3.7 46.9  4.0 45.7  4.7 46.1  5.0 0.111
LV end-syst. d., mm 31.7  3.4 32.4  3.9 30.3  3.6 27.4  4.3 29.2  3.2 <0.001a,b,c
LV fractional sh., % 33.7  4.3 33.5  5.5 35.6  4.0 40.2  5.6 36.6  4.9 <0.001a,b,e
Septal end-dias. th., mm 9.8  1.0 9.7  0.9 9.7  1.0 9.8  1.3 9.5  1.3 0.920
PW end-diast. th., mm 9.9  0.9 9.7  0.9 9.8  1.1 9.8  1.3 9.6  1.3 0.891
LV EF, % 60.5  6.0 62.2  8.1 63.6  3.9 65.5  9.0 66.5  7.6 0.024d
LA end-syst. area, cm2 14.4  3.2 15.3  2.5 14.6  2.4 14.2  2.4 15.5  2.6 0.566
RA end-syst. area, cm2 14.5  2.8 14.4  3.2 14.7  2.4 13.8  4.5 15.1  1.9 0.742
RV diast. surface, cm2 17.1  3.1 17.5  4.7 16.8  3.8 14.5  3.8 16.2  2.8 0.055
RV syst. surface, cm2 9.3  2.4 9.3  2.5 9.4  2.6 8.2  2.3 8.8  2.1 0.388
RV free wall th., mm 3.8  0.8 4.0  0.7 4.0  0.5 3.9  0.6 3.8  0.7 0.751
RV EF, % 53.7  9.8 52.6  7.0 53.0  8.9 54.5  8.2 53.7  7.2 0.949
RV fractional sh., % 26.1  5.2 25.4  4.5 26.1  5.9 26.7  4.8 25.9  4.2 0.932
RVOT syst. amp., mm 19.8  3.0 20.0  3.2 19.8  2.0 18.5  2.6 17.6  2.5 0.011c,d
TAPSE, mm 21.7  2.8 22.7  2.8 22.1  2.8 22.1  3.9 22.6  2.1 0.684
Syst. velocity, cm/s 23  9 20  4 23  11 23  6 24  7 0.420
Em velocity, cm/s 23  9 22  6 20  4 22  5 25  10 0.432
Am velocity, cm/s 26  12 23  7 23  6 27  8 24  10 0.487
E/A ratio 9.3  3.0 10.9  5.5 9.0  1.9 9.0  3.7 1.1  3.0 0.153
Tei index 0.41  0.14 0.44  0.11 0.44  0.11 0.47  0.14 0.44  0.11 0.579
LV: left ventricle, RV: right ventricle, diast.: diastolic, syst.: systolic, d.: dimension; sh.: shortening, th.: thickness; EF: ejection
fraction; amp.: amplitude; PW: posterior wall, RVOT: right ventricle outflow tract diameter, TAPSE: tricuspid annular plane systolic
excursion, Em: early-diastolic myocardial velocity, Am: late-diastolic myocardial velocity.
a PAI vs. SSc.
b Vascular disease without PAI vs. SSc.
c Vascular disease without PAI vs. Healthy controls.
d PAI vs. Healthy controls.
e Patients without vascular disease vs. SSc.
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Table 6 Comparison of Behc¸et’s syndrome patients with
pulmonary artery involvement with and without pulmonary
artery hypertension.
n (%) Elevated
sPAP (þ)
n Z 5
Elevated
sPAP ()
n Z 25
P
Males, n (%) 4 (80) 23 (92) 0.433
Disease duration,a years 6  3 6  6 0.963
Smoker, n (%) 1 (20) 6 (24) 1.0
PAA based on thorax CT
at diagnosis, n (%)
5 (100) 21 (84) 1.0
Active disease based on
CT taken at the study,
n (%)
1 (20) 4 (16) 0.827
Patients with lower
extremity DVT, n (%)
4 (80) 14 (56) 0.622
Patients with VCI
thrombosis, n (%)
2 (40) 5 (20) 0.565
Patients with exercise
dyspnea, n (%)
4 (80) 12 (48) 0.336
DLCO, % 64  10 75  16 0.165
Pro-BNP, fmol/mL 483  82 714  405 0.274
Six-MWT, m 480  69 487  83 0.868
Patients with any ECG
abnormality, n (%)
3 (60) 4 (16) 0.068
BS: Behcet’s syndrome, PAH: pulmonary artery hypertension,
CT: computed tomography, PA: pulmonary artery, VCI: vena
cava inferior thrombosis, DVT: deep vein thrombosis, ECG:
electrocardiography, DLCO: diffusing capacity of carbon
monoxide, Pro-BNP: pro-brain natriuretic peptide. Six-MWT: six-
minute walking test.
a Duration since the onset of pulmonary disease.
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we only studied surviving BS patients with PAI, of whom
only a few had active disease. In our previous retrospective
analysis that led to this controlled study, we had observed
significantly higher estimated sPAP levels in BS patients who
had had a fatal outcome.11 Therefore, the levels of sPAP
would likely have been higher if we had included patients
with more active disease and those who had been diag-
nosed earlier in their disease course.
We observed that PAA had disappeared with immunosup-
pressive therapy by the time we conducted the study, as
reported previously.26 Although residual occlusions had
developed as a result of the healing process in some patients,
the arterial vasculature resumed its normal radiological
appearance in other patients. Nevertheless, arteritis in BS
patients remained ongoing with a relapsing course and a high
acute phase response. Consequently, these patients continued
to receive immunosuppressives, as shown in Table 1.
An interestingly high prevalence of dyspnea was found in
BS patients with vascular disease with (42%) or without PAI
(53%). It is uncertain whether this result was related to PAH
because estimated sPAP elevations were mild, and patients
with vascular involvement without PAI also suffered
substantially from dyspnea, but they did not show impres-
sive sPAP and DLCO abnormalities. Dyspnea could not be due
to interstitial lung disease because this pathology is not
a feature of BS. In addition, no interstitial lung changeswere observed in thorax CTs. Although dyspnea as defined
by the patients was not severe (NYHA II), its association
with vascular involvement is intriguing and requires further
study using more objective methods.
The high prevalence of venous thrombosis in BS patients
with vascular disease with and without PAI suggests the
possibility of unrecognized, repeated minor pulmonary
thromboemboli27 as the causes of mild PAH, dyspnea and low
DLCO. However, this hypothesis seems quite unlikely in BS
based on several lines of evidence: (a). there is a relative
absence of embolic phenomena in BS patients despite a high
prevalence of venous thrombosis based on a large Japanese
autopsy registry10 and our clinical experiences over 30 years;
(b). the thromboses observed are strongly adherent to the
vessel wall and contain inflammatory cell infiltrates, devel-
oping as a complication to an underlying vasculitis seen in
these patients6,7; (c). there is no associated coagulation
abnormality in BS7; and (d). immunosuppressive agents,
rather than anti-coagulants, are more effective for the
treatment of thrombosis in BS.28 Pulmonary arterial vascu-
litis that involves small or micro vessels is the most likely
explanation for the abnormalities that were found in the
current study; however, further studies are needed.
Mild cardiac dysfunction and silent myocardial ischemia
have been reported previously in BS patients.29e31 Simi-
larly, we found mild LV systolic and RV diastolic dysfunction
in BS patients with vascular disease, which suggests
a primary myocardial involvement. A high frequency of ECG
abnormalities and high pro-BNP levels are further evidence
for the cardiac micro-vessel vasculitis.
We observed that the six-MWT distance was decreased in
BS patients with vascular disease without PAI. We had previ-
ously reported that venous claudication was present in about
1/4 of BS patients with DVT in the lower extremities.32Venous
claudication and dyspnea may play a role in the reduced
exercise tolerance that was observed in this group.
Both ET-1 and VEGF are increased in BS.33,34 However,
the levels of both markers were not increased in the
current study. ET-1 was elevated only in SSc patients, and
VEGF levels were similar between the study groups.
Our study had some limitations. We could not perform
right heart catheterization, which is the definitive method
of assessing sPAP in BS patients, due to the risk of the
induction of arterial complications that are unique in these
patients as a result of the characteristic pathergy
phenomenon in BS.14e16 Instead, we used echocardiography
to estimate sPAP levels and set 35 mmHg as the cut-off
level to discriminate high and low levels. Our choice was
somewhat arbitrary, but this cut-off level is consistent with
that reported by other authors who have used the same
threshold for their purposes.35e41 However, the recent ESC
guidelines warrant further investigation, primarily for sPAP
values estimated by echocardiography greater than
50 mmHg.25 Adherence to these guidelines in our study
would have left only 2 patients with SSc with a definite
diagnosis of PAH. This reduction would have been too
restrictive for our purposes. In general, the correlation of
pulmonary pressure between echocardiography and right
heart catheterization is good.42e44 However, under- and
over-estimations occur.38,43,44 Under-estimation results
from the absence or inadequate visualization of the
tricuspid regurgitant jet.38,44 The reason for overestimation
1746 E. Seyahi et al.is largely unknown but may stem from technical prob-
lems.38,44 For these reasons, ESC guidelines suggest that
a reliable cut-off value for PAH using echocardiography
cannot be defined and that echocardiography cannot be
used as an effective screening tool to assess mild to
moderate PAH (sPAP < 50 mmHg).25 This criticism is why we
called what was observed elevated estimated sPAP instead
of PAH. Furthermore, the fact that the echocardiograms
were assessed in a blinded manner and that we formally
evaluated intra-observer variability makes us somewhat
more confident in our results. The limited number of
patients that were included in each study group was
another limitation, especially because many of our obser-
vations were subject to multiple comparisons. It follows
that some of our observations should be regarded as
hypothesis-generating rather than definitive findings.
In conclusion, this study suggested that BS may cause
mild elevations in estimated sPAP with a decrease in DLCO
and an increase in pro-BNP, especially when the pulmonary
arteries are involved. These new findings, with the reduced
exercise tolerance and impairment in cardiac function that
were observed in BS patients with vascular disease, suggest
that BS may affect small/micro vessels of the heart and
lungs in addition to the larger pulmonary arteries.
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